DUBLIN--(BUSINESS WIRE)--Alkermes plc (NASDAQ: ALKS) today reported financial results for the twelve months ended Dec. 31, 2015 and provided financial expectations for 2016.
“Alkermes has a diversified CNS business poised for significant growth over the coming years. In 2015, we continued to successfully execute on our business plan, highlighted by the robust revenue growth of VIVITROL® and the launch of our novel, long-acting antipsychotic ARISTADA® for the treatment of schizophrenia,” said Richard Pops, Chief Executive Officer of Alkermes.
